BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci. 2014;1317:32-38. [PMID: 24840548 DOI: 10.1111/nyas.12456] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Balbi GGM, Domingues V, Balbi GGM, De Jesús GR, Levy RA. Use of synthetic and biologic DMARDs during pregnancy. Expert Rev Clin Immunol 2019;15:27-39. [PMID: 30365902 DOI: 10.1080/1744666X.2019.1541739] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Dauti A, Gerstl B, Chong S, Chisholm O, Anazodo A. Improvements in Clinical Trials Information Will Improve the Reproductive Health and Fertility of Cancer Patients. J Adolesc Young Adult Oncol 2017;6:235-69. [PMID: 28207285 DOI: 10.1089/jayao.2016.0084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
3 Bazzani C, Andreoli L, Agosti M, Nalli C, Tincani A. Antirheumatic drugs and reproduction in women and men with chronic arthritis. RMD Open 2015;1:e000048. [PMID: 26557371 DOI: 10.1136/rmdopen-2015-000048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
4 Ponticelli C, Moroni G. Fetal Toxicity of Immunosuppressive Drugs in Pregnancy. J Clin Med 2018;7:E552. [PMID: 30558290 DOI: 10.3390/jcm7120552] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
5 Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 2021;193:E1129-36. [PMID: 34312166 DOI: 10.1503/cmaj.202391] [Reference Citation Analysis]
6 Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges 2015;13:277-89; quiz 290. [PMID: 25819232 DOI: 10.1111/ddg.12596] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
7 Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord 2016;9:198-210. [PMID: 27134675 DOI: 10.1177/1756285616631897] [Cited by in Crossref: 60] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
8 Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy 2016;17:1539-47. [DOI: 10.1080/14656566.2016.1197204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
9 Koh YP, Tian EA, Oon HH. New changes in pregnancy and lactation labelling: Review of dermatologic drugs. Int J Womens Dermatol 2019;5:216-26. [PMID: 31700976 DOI: 10.1016/j.ijwd.2019.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
10 Wong PKK, Bagga H, Barrett C, Hanrahan P, Johnson D, Katrib A, Leder K, Marabani M, Pentony P, Riordan J, White R, Young L. A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia. Intern Med J 2017;47:491-500. [PMID: 28101910 DOI: 10.1111/imj.13371] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
11 Østensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse ME, Costedoat-Chalumeau N, Cutolo M, Dolhain R, Fenstad MH, Förger F, Wahren-Herlenius M, Ruiz-Irastorza G, Koksvik H, Nelson-Piercy C, Shoenfeld Y, Tincani A, Villiger PM, Wallenius M, von Wolff M. State of the art: Reproduction and pregnancy in rheumatic diseases. Autoimmun Rev 2015;14:376-86. [PMID: 25555818 DOI: 10.1016/j.autrev.2014.12.011] [Cited by in Crossref: 119] [Cited by in F6Publishing: 90] [Article Influence: 17.0] [Reference Citation Analysis]
12 Alijotas-reig J, Esteve-valverde E, Ferrer-oliveras R. Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos. Medicina Clínica 2016;147:352-60. [DOI: 10.1016/j.medcli.2016.05.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
13 Plachouri KM, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. J Dermatolog Treat 2019;30:668-73. [PMID: 30428753 DOI: 10.1080/09546634.2018.1544413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox Pharmacovigilance Center. Reprod Toxicol 2016;60:29-32. [PMID: 26806369 DOI: 10.1016/j.reprotox.2016.01.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
15 Tsur A, Hughes GC, Shoenfeld Y, Carp H. Interdisciplinary exchange of ideas: progestagens for autoimmunity, biologics for pregnancy complications. Immunol Res 2015;61:31-4. [PMID: 25550090 DOI: 10.1007/s12026-014-8621-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Cornelius DC, Castillo J, Porter J, Amaral LM, Campbell N, Paige A, Thomas AJ, Harmon A, Cunningham MW Jr, Wallace K, Herse F, Wallukat G, Dechend R, LaMarca B. Blockade of CD40 ligand for intercellular communication reduces hypertension, placental oxidative stress, and AT1-AA in response to adoptive transfer of CD4+ T lymphocytes from RUPP rats. Am J Physiol Regul Integr Comp Physiol 2015;309:R1243-50. [PMID: 26310940 DOI: 10.1152/ajpregu.00273.2015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
17 Grunewald S, Staubach P. Dermatologische topische und Systemtherapie in der Schwangerschaft. Hautarzt 2017;68:127-35. [DOI: 10.1007/s00105-016-3921-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
18 Gerosa M, Meroni PL, Cimaz R. Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opinion on Drug Safety 2014;13:1591-9. [DOI: 10.1517/14740338.2014.951326] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
19 Jappe U, Beckert H, Bergmann KC, Gülsen A, Klimek L, Philipp S, Pickert J, Rauber-Ellinghaus MM, Renz H, Taube C, Treudler R, Wagenmann M, Werfel T, Worm M, Zuberbier T. Biologics for atopic diseases: Indication, side effect management, and new developments. Allergol Select 2021;5:1-25. [PMID: 33426426 DOI: 10.5414/ALX02197E] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Genovese G, Derlino F, Berti E, Marzano AV. Treatment of Autoimmune Bullous Diseases During Pregnancy and Lactation: A Review Focusing on Pemphigus and Pemphigoid Gestationis. Front Pharmacol 2020;11:583354. [PMID: 33117178 DOI: 10.3389/fphar.2020.583354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, Ramonda R, Grava C, Raffeiner B, Ravagni P, De Vita S, Ruffatti A. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine 2017;84:169-73. [DOI: 10.1016/j.jbspin.2016.03.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
22 Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Review of Vaccines 2016;15:239-56. [DOI: 10.1586/14760584.2016.1115351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
23 Al-Mogairen S. Does Abatacept Induce Testicular Toxicity? Arch Rheumatol 2020;35:220-5. [PMID: 32851371 DOI: 10.46497/ArchRheumatol.2020.7164] [Reference Citation Analysis]
24 Greenfield AL, Hauser SL. B-cell Therapy for Multiple Sclerosis: Entering an era. Ann Neurol 2018;83:13-26. [PMID: 29244240 DOI: 10.1002/ana.25119] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 48.0] [Reference Citation Analysis]
25 Cordero-coma M, Salazar-méndez R, Yilmaz T. Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues. Expert Opinion on Drug Safety 2015;14:1071-86. [DOI: 10.1517/14740338.2015.1044969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Wieringa JW, van der Woude CJ. Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2020;44-45:101665. [PMID: 32359679 DOI: 10.1016/j.bpg.2019.101665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Kümpfel T, Thiel S, Meinl I, Ciplea AI, Bayas A, Hoffmann F, Hofstadt-van Oy U, Hoshi M, Kluge J, Ringelstein M, Aktas O, Stoppe M, Walter A, Weber MS, Ayzenberg I, Hellwig K. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany. Neurol Neuroimmunol Neuroinflamm 2021;8:e913. [PMID: 33334856 DOI: 10.1212/NXI.0000000000000913] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Ngian GS, Briggs AM, Ackerman IN, Van Doornum S. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis 2016;19:834-43. [PMID: 27125255 DOI: 10.1111/1756-185X.12860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Wong PK, Hanrahan P. Management of vaccination in rheumatic disease. Best Practice & Research Clinical Rheumatology 2018;32:720-34. [DOI: 10.1016/j.berh.2019.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GDV, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH. Proceedings From the American College of Rheumatology Reproductive Health Summit: The Management of Fertility, Pregnancy, and Lactation in Women With Autoimmune and Systemic Inflammatory Diseases: Pregnancy in Autoimmune and Systemic Inflammatory Diseases. Arthritis Care & Research 2015;67:313-25. [DOI: 10.1002/acr.22516] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
32 Wieringa JW, Driessen GJ, Van Der Woude CJ. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. Expert Rev Gastroenterol Hepatol 2018;12:811-8. [PMID: 29972674 DOI: 10.1080/17474124.2018.1496820] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
33 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. WJR 2015;5:50. [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]